Ghallab et al., 2024 - Google Patents
Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasisGhallab et al., 2024
View HTML- Document ID
- 11796190920631531087
- Author
- Ghallab A
- González D
- Strängberg E
- Hofmann U
- Myllys M
- Hassan R
- Hobloss Z
- Brackhagen L
- Begher-Tibbe B
- Duda J
- Drenda C
- Kappenberg F
- Reinders J
- Friebel A
- Vucur M
- Turajski M
- Seddek A
- Abbas T
- Abdelmageed N
- Morad S
- Morad W
- Hamdy A
- Albrecht W
- Kittana N
- Assali M
- Vartak N
- van Thriel C
- Sous A
- Nell P
- Villar-Fernandez M
- Cadenas C
- Genc E
- Marchan R
- Luedde T
- Åkerblad P
- Mattsson J
- Marschall H
- Hoehme S
- Stirnimann G
- Schwab M
- Boor P
- Amann K
- Schmitz J
- Bräsen J
- Rahnenführer J
- Edlund K
- Karpen S
- Simbrunner B
- Reiberger T
- Mandorfer M
- Trauner M
- Dawson P
- Lindström E
- Hengstler J
- Publication year
- Publication venue
- Journal of hepatology
External Links
Snippet
Background & Aims Cholemic nephropathy (CN) is a severe complication of cholestatic liver diseases for which there is no specific treatment. We revisited its pathophysiology with the aim of identifying novel therapeutic strategies. Methods Cholestasis was induced by bile …
- 241000699670 Mus sp. 0 title abstract description 85
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ghallab et al. | Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis | |
| Chalasani et al. | Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension | |
| Yoshino | Edaravone for the treatment of amyotrophic lateral sclerosis | |
| Krones et al. | NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice | |
| EP3054940B1 (en) | Compositions and methods for treating non-alcoholic steatohepatitis | |
| US20070015796A1 (en) | Compositions and methods for treatment of fibrosis | |
| Ellison et al. | Why your mother was right: how potassium intake reduces blood pressure | |
| US9726659B2 (en) | CMPF as a biomarker for diabetes and associated methods | |
| Marzioni et al. | Taurocholate prevents the loss of intrahepatic bile ducts due to vagotomy in bile duct-ligated rats | |
| JP2003505336A (en) | Glucocorticoid receptor antagonist for treatment of dementia | |
| Yu et al. | Hepatoprotective effect of vitamin C on lithocholic acid-induced cholestatic liver injury in Gulo (−/−) mice | |
| Gotoh et al. | Genetic knockout and pharmacologic inhibition of NCX2 cause natriuresis and hypercalciuria | |
| Vera et al. | Moderate hyperbilirubinemia improves renal hemodynamics in ANG II-dependent hypertension | |
| US20220387370A1 (en) | Methods of reducing neurological damage in wilson disease patients | |
| Tao et al. | Omentin-1 ameliorates experimental inflammatory bowel disease via Nrf2 activation and redox regulation | |
| Giani et al. | Renal tubular angiotensin converting enzyme is responsible for nitro-L-arginine methyl ester (L-NAME)-induced salt sensitivity | |
| Cury et al. | Protective effect of octreotide and infliximab in an experimental model of indomethacin-induced inflammatory bowel disease | |
| Shey et al. | Recurrent calcium nephrolithiasis associated with primary aldosteronism | |
| Xie et al. | Fluid resuscitation via the rectum ameliorates hemodynamic disorders through adjusting aquaporin expression in an experimental severe acute pancreatitis model | |
| Muto et al. | Effect of oral glucose administration on serum potassium concentration in hemodialysis patients | |
| Fujita et al. | A low-carbohydrate diet improves glucose metabolism in lean insulinopenic Akita mice along with sodium-glucose cotransporter 2 inhibitor | |
| Wang et al. | ER Stress is Activated and Involved in Disuse-Induced Muscle Atrophy | |
| WO2022105870A1 (en) | Methods of treating systemic lupus erythematosus using btk inhibitors | |
| Zhang et al. | α-chaconine facilitates chondrocyte pyroptosis and nerve ingrowth to aggravate osteoarthritis progression by activating NF-κB signaling | |
| EP4028012A1 (en) | Compound for inhibiting cell death |